Search results

...'''cangrelor''' is an [[purinergic P2Y receptor antagonist]]s that is a [[platelet aggregation inhibitor]]. ...Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW et al.| title=Effect of platelet inhibition with cangrelor during PCI on ischemic events. | journal=N Engl J

{{r|Platelet}}

{{r|Platelet transfusion}}

...antagonize or impair any mechanism leading to blood [[platelet activation|platelet aggregation]], whether during the phases of activation and shape change or Inhibitors of the [[platelet glycoprotein GPIIb-IIIa complex]] (GPIs) include the [[monoclonal antibody]

{{r|Platelet}}

{{r|Platelet}}

==Anatomy of a platelet== ...brand factor]]), the contents of which are released upon activation of the platelet. These granule contents play an important role in both [[hemostasis]] and i

...nce of [[fibrin]] strands following the mixing of plasma with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of t

...nism of [[phagocytosis]]. They produce [[leukotriene]] C₄ and [[platelet activation factor]] (PAF). <ref name=Ganong>{{citation ...Ganong, p. 508</ref> Especially infectious parasites produce inhibitors of platelet aggregation.<ref name=Liu>{{citation

...of [[hematoepoesis]]: generation of [[erythrocyte]]s, [[leukocyte]]s and [[platelet]]s from [[hematopoetic stem cell]]s.

{{r|Platelet||**}}

{{r|Platelet-derived growth factor receptor||**}}

...nthase]] by acetylating its terminal amino group. Aspirin also inhibits [[platelet]] aggregation and is used in the prevention of arterial and venous [[thromb Individuals in whom platelet function assays demonstrate resistance to aspirin are less likely to have c

...s]] include [[leukocyte]]s for immune and infection-fighting action, and [[platelet]]s for clotting.

...eptor]]s, and [[purinoceptor P2Y12|purinoceptor P2Y₁₂]] (causes platelet aggregation).

*[[Platelet]]s per unit volume

...ansduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway."<ref>{{MeSH}}</ref>

...('''TTP''') is "an acquired, congenital, or familial disorder caused by [[platelet aggregation]] with [[thrombosis]] in terminal arterioles and capillaries. C

...hich leads to profound low [[white blood cell]], [[red blood cell]], and [[platelet]] counts.

...does not irreversibly inhibit [[cyclooxygenase]] and thus is not an [[anti-platelet agent]].